相关实验视频

Updated: Sep 12, 2025

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Incorporation of a Survivable Liver Biopsy Procedure in Mice to Assess Non-alcoholic Steatohepatitis NASH Resolution

Published on: April 16, 2019

基于FAERS数据库对伊姆格卢塞拉斯的不良反应的评估和研究

Pan Hong¹, Qingbo Zhou²

¹Department of Hematology, Shaoxing People's Hospital, Shaoxing, Zhejiang, China.

Orphanet journal of rare diseases

|August 8, 2025

概括

这项研究分析了FDA的imiglucerase在Gaucher病治疗中的不良事件数据. 虽然最初的信号暗示了一般和受伤相关的问题,但这些都是人工物;关键发现指出了潜在的骨问题,需要持续的药物监测.

科学领域:

药监和药物安全药监和药物安全
罕见疾病和遗传性疾病
生物药物和酶替代疗法

背景情况:

氏病是一种罕见的遗传疾病,需要酶替代疗法.
免疫葡萄糖酶是高氏病的关键治疗方法,需要持续监测安全性.
美国食品和药物管理局的不良事件报告系统 (FAERS) 是市场后药物监测的关键数据库.

研究的目的:

为了评估与Gaucher病患者的imiglucerase相关的不良药物反应 (ADRs).
识别和分析安全信号使用来自FAERS的大规模真实世界的数据.
通过指示区分真实的ADR与报告文物和混.

主要方法:

从FAERS (2004年第一季度 - 2023年第四季度) 分析了超过1.66亿份不良事件报告.
使用多种不成比例方法 (ROR,PRR,BCPNN,MGPS) 进行信号检测.
在系统器官类 (SOC) 和首选术语 (PT) 中检查的不良事件.

主要成果:

最初的分析表明,在一般性疾病,伤害,感染和神经系统疾病方面有显著信号.
确定了一个主要的报告文物 ("Gaucher病"PT),掩盖了真正的ADRs.
经过人工物调整后,信号包括提升的奇托里奥酶,酸酸酶和骨梗塞,显著的骨信号可能被指示混.

结论:

持续对伊姆格卢塞拉斯的药物监测是必不可少的,特别是在脆弱的患者群体.
应特别注意孕妇,长期使用者和患有肝胆或骨并发症的患者.
区分真实的不良反应与报告人工物和疾病进展对于准确的安全评估至关重要.

关键词:

药物不良反应药物不良反应在FAERS数据库中,我们可以找到FAERS数据库.戈舍氏病是戈舍氏病的一种疾病.在imiglucerase中使用.药物监督药物监督药物监督

更多相关视频

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Fecal Glucocorticoid Analysis: Non-invasive Adrenal Monitoring in Equids

Published on: April 25, 2016

Evaluation of the Storage Stability of Extracellular Vesicles

Evaluation of the Storage Stability of Extracellular Vesicles

Published on: May 22, 2019

相关概念视频

Pharmacovigilance

Pharmacovigilance

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

Insulin: Dosing Regimen and Adverse Effects

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...